175 related articles for article (PubMed ID: 25870249)
1. Regulation of vascular endothelial growth factor in prostate cancer.
de Brot S; Ntekim A; Cardenas R; James V; Allegrucci C; Heery DM; Bates DO; Ødum N; Persson JL; Mongan NP
Endocr Relat Cancer; 2015 Jun; 22(3):R107-23. PubMed ID: 25870249
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
5. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
7. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
Bishop JL; Davies A; Ketola K; Zoubeidi A
Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
9. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
11. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.
Larsson P; Syed Khaja AS; Semenas J; Wang T; Sarwar M; Dizeyi N; Simoulis A; Hedblom A; Wai SN; Ødum N; Persson JL
Int J Cancer; 2020 Mar; 146(6):1686-1699. PubMed ID: 31381135
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
13. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
14. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
18. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
[TBL] [Abstract][Full Text] [Related]
19. Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
Mitsunari K; Miyata Y; Asai A; Matsuo T; Shida Y; Hakariya T; Sakai H
Transl Res; 2016 Sep; 175():116-28. PubMed ID: 27140699
[TBL] [Abstract][Full Text] [Related]
20. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
